Vitrasert Implant Tablet 4.5Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • Weekly Ad

Vitrasert: Implant tablet (4.5mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

GANCICLOVIR (gan SYE kloe veer) is an antiviral medicine. It is used to treat infections caused by certain kinds of viruses. The implant is used to treat cytomegalovirus (CMV) eye infections. The implant will only treat the eye it has been placed into, and it is not a cure for CMV.

In-Depth Information
Select a Medication

Vitrasert 4.5mg Ophthalmic Implant

NDC: 617720002
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Cytomegalovirus (CMV) Disease Prophylaxis, Cytomegalovirus (CMV) Retinitis Prophylaxis

Storage Information
Store at room temperature (between 59 to 86 degrees F)
Protect from light
Protect from freezing
Avoid excessive heat (above 104 degrees F)
Vitrasert 4.5mg Ophthalmic Implant

Reported Side Effects for Vitrasert 4.5mg Ophthalmic Implant

Endophthalmitis Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Retinopathy Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Bleeding Within The Eye Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Keratopathy Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Blood In The Eye Incidence:
1.0-5.0%*
Severity: MODERATE
Onset: DELAYED
High Eye Blood Pressure Incidence:
1.0-5.0%*
Severity: SEVERE
Onset: DELAYED
Eye Inflammation Incidence:
1.0-5.0%*
Severity: SEVERE
Onset: DELAYED
Cataracts Incidence:
1.0-5.0%*
Severity: MODERATE
Onset: DELAYED
Corneal Opacification Incidence:
1.0-5.0%*
Severity: SEVERE
Onset: DELAYED
Eye Inflammatoin Incidence:
>5.0%*
Severity: SEVERE
Onset: DELAYED
Red Eyes Incidence:
5.0%*
Severity: MODERATE
Onset: EARLY
Retinal Detachment Incidence:
8.0-20.0%*
Severity: SEVERE
Onset: DELAYED
Visual Impairment Incidence:
>10.0%*
Severity: SEVERE
Onset: EARLY
Eye Irritation Incidence:
20.0%*
Severity: MILD
Onset: RAPID
Blurred Vision Incidence:
60.0%*
Severity: MODERATE
Onset: EARLY
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

THIRD Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Vitrasert

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5